Category: Consulting

Neurological diseases remain one of the most pressing areas of unmet medical need. For many rare or monogenic disorders of the central nervous system (CNS), there are no effective therapies available today. At the same time, advances in gene therapy – delivery technologies, vector design, and clinical endpoints – are creating a window of opportunity that investors cannot ignore.

While large pharmaceutical companies are often cautious in this space, Family Offices and specialized funds have the chance to catalyze breakthrough innovation by supporting early-stage biotech companies.

---

Why Neurology is Attractive for Gene Therapy

1. High Unmet Need
2. Scientific Feasibility
3. Measurable Proof-of-Concept
4. Limited Competition in Niche Indications

---

The Role of Family Offices

Family Offices are uniquely positioned to:

• Provide patient capital to bridge the “valley of death” from academic discovery to seed-stage biotech.
• Build long-term partnerships with founders and academic spin-outs.
• Shape the future pipeline by funding areas that large investors overlook but where medical need is greatest.

Risks are real – high attrition in clinical trials, regulatory hurdles, and capital intensity – yet these are precisely the areas where risk-tolerant, long-horizon investors can make the most meaningful difference.

---

Examples of Opportunity Areas

• Pediatric neuro-metabolic disorders with defined gene defects.
• Neurodevelopmental syndromes with strong academic research traction.
• Universities and research hospitals in Europe, the US, and Japan currently spinning out new CNS gene therapy ventures.

---

Conclusion

Neurology is entering a new era: with gene therapy, diseases once considered untreatable may finally become accessible to medicine. For Family Offices, this is not only an opportunity to invest – but to play a pivotal role in shaping the next wave of innovation.

I am happy to exchange perspectives with investors, founders, and scientists interested in this field – and to connect Family Offices with opportunities that combine scientific rigor, clinical relevance, and business potential.

I’ve always admired the Mercedes 300 SL Gullwing. This wasn’t just a beautiful car – it represented radical engineering leaps. Fuel injection, lightweight frames, bold design choices. At the time, many doubted whether these concepts would succeed.

Fast-forward 70 years: it is not just a classic, it is a benchmark of vision, courage, and long-term value.

Biotech investments feel very similar. On the surface, a project might look like “just another prototype.” But beneath the surface, there may be groundbreaking science – if it’s engineered and developed with the right vision and discipline.

The challenge for investors and Family Offices is this: how do you know if you’re looking at the next Gullwing of medicine – or a concept car that won’t survive the road?

That’s where rigorous evaluation matters. Just as restoring or buying a classic car requires deep expertise, assessing biotech opportunities demands a structured view of science, CMC, regulatory, and market access.

Visionary engineering built the icons of yesterday. Visionary science will build the medicines of tomorrow.